Clinical features and CKD-related quality of life in patients with CKD G3a and CKD G3b in China: results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE)

Zhangzhe Peng, Jinwei Wang, Qiongjing Yuan, Xiangcheng Xiao, Hui Xu, Yanyun Xie, Wei Wang, Ling Huang, Yong Zhong, Xiang Ao, Luxia Zhang, Minghui Zhao, Lijian Tao, Qiaoling Zhou, C-STRIDE study group, Zhangzhe Peng, Jinwei Wang, Qiongjing Yuan, Xiangcheng Xiao, Hui Xu, Yanyun Xie, Wei Wang, Ling Huang, Yong Zhong, Xiang Ao, Luxia Zhang, Minghui Zhao, Lijian Tao, Qiaoling Zhou, C-STRIDE study group

Abstract

Background: This study aimed to compare clinical features and health-related quality of life (HRQoL) in the Chinese chronic kidney disease (CKD) 3 population and determined the necessity of the subdivision of CKD3 in Chinese patients with CKD.

Methods: Participants with stage 3 CKD (18-74 years of age) were recruited at 39 clinical centers located at 28 cities in 22 provinces of China. The sociodemographic status, medical history, anthropometric measurements, and lifestyle behaviors were documented at entry, and blood and urine samples were collected. The estimated glomerular filtration rate was calculated using the CKD-EPI creatinine equation. The HRQoL was evaluated using the kidney disease quality-of-life instrument. A linear regression model was used to estimate the association between HRQoL and CKD stages (G3b vs G3a).

Results: The levels of intact parathyroid hormone, systolic blood pressure, uric acid, and high-density lipoprotein cholesterol were statistically significantly higher, whereas the levels of serum bicarbonate and hemoglobin were statistically significantly lower in the G3b group compared with the G3a group. Compared with CKD G3a group, the proportions of subjects with hyperuricemia and anemia were significantly higher in CKD G3b group (61.4% vs. 52.0% and 26.4% vs. 17.9%, respectively, P< 0.01). The HRQoL scores in "physical functioning (PCS)", "symptoms and problems", "effects of the kidney disease" and "burden of the kidney disease" were statistically significantly lower in the CKD G3b group compared with the CKD G3a group (90.88 ± 11.05 vs. 89.30 ± 11.52, 88.29 ± 11.94 vs. 86.49 ± 13.45, 55.86 ± 26.40 vs. 52.10 ± 27.64, 46.56 ± 8.16 vs. 44.51 ± 9.22, respectively, P< 0.01). Further, CKD G3b was associated with a lower score of physical functioning compared with G3a (regression coefficient =-1.12 [95%CI: -2.23, -0.16]).

Conclusions: The preliminary results of this study suggested that modest differences existed in many important clinical features and KDQoL between patients with G3a and G3b CKD in a Chinese population. Also, a significant association between CKD3 subdivision of the disease and PCS was detected. Although further work is needed, we can speculate based on these results the CKD3 subdivision may be clinically meaningful for Chinese patients with CKD.

Keywords: Chronic kidney disease stage 3; Clinical features; Health-related quality of life; Subdivision.

Conflict of interest statement

Ethics approval and consent to participate

This study was approved by the ethics committee of Peking University First Hospital and Central South University Xiangya Hospital, China, and was in adherence with the Declaration of Helsinki. All subjects signed informed consent forms before data collection.

Consent for publication

Not applicable.

Competing interests

The authors declare that they do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. Ruggenenti P, Cravedi P, Remuzzi G. Mechanisms and treatment of CKD. J Am Soc Nephrol. 2012;23(12):1917–1928. doi: 10.1681/ASN.2012040390.
    1. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–272. doi: 10.1016/S0140-6736(13)60687-X.
    1. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, Chen M, He Q, Liao Y, Yu X, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815–822. doi: 10.1016/S0140-6736(12)60033-6.
    1. Honeycutt AA, Segel JE, Zhuo X, Hoerger TJ, Imai K, Williams D. Medical costs of CKD in the Medicare population. J Am Soc Nephrol. 2013;24(9):1478–1483. doi: 10.1681/ASN.2012040392.
    1. Hu JR, Coresh J. The public health dimension of chronic kidney disease: what we have learnt over the past decade. Nephrol Dial Transplant. 2017;32(suppl_2):ii113–ii120. doi: 10.1093/ndt/gfw416.
    1. Zhang L, Wang H. Chronic kidney disease epidemic: cost and health care implications in China. Semin Nephrol. 2009;29(5):483–486. doi: 10.1016/j.semnephrol.2009.06.012.
    1. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80(1):17–28. doi: 10.1038/ki.2010.483.
    1. Zhang L, Long J, Jiang W, Shi Y, He X, Zhou Z, Li Y, Yeung RO, Wang J, Matsushita K, et al. Trends in Chronic Kidney Disease in China. N Engl J Med. 2016;375(9):905–906. doi: 10.1056/NEJMc1602469.
    1. Cao X, Zhou J, Yuan H, Wu L, Chen Z. Chronic kidney disease among overweight and obesity with and without metabolic syndrome in an urban Chinese cohort. BMC Nephrol. 2015;16:85. doi: 10.1186/s12882-015-0083-8.
    1. Yuan J, Zou XR, Han SP, Cheng H, Wang L, Wang JW, Zhang LX, Zhao MH, Wang XQ, group CSs Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients: results from the Chinese cohort study of chronic kidney disease (C-STRIDE) BMC Nephrol. 2017;18(1):23. doi: 10.1186/s12882-017-0441-9.
    1. Gao B, Zhang L, Wang H, Zhao M. Chinese cohort study of chronic kidney disease: design and methods. Chin Med J. 2014;127(11):2180–2185.
    1. Chow SK, Tam BM. Is the kidney disease quality of life-36 (KDQOL-36) a valid instrument for Chinese dialysis patients? BMC Nephrol. 2014;15:199. doi: 10.1186/1471-2369-15-199.
    1. Tao X, Chow SK, Wong FK. Determining the validity and reliability of the Chinese version of the Kidney Disease Quality of Life Questionnaire (KDQOL-36) BMC Nephrol. 2014;15:115. doi: 10.1186/1471-2369-15-115.
    1. Gorodetskaya I, Zenios S, McCulloch CE, Bostrom A, Hsu CY, Bindman AB, Go AS, Chertow GM. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68(6):2801–2808. doi: 10.1111/j.1523-1755.2005.00752.x.
    1. Patel SS, Kimmel PL, Singh A. New clinical practice guidelines for chronic kidney disease: a framework for K/DOQI. Semin Nephrol. 2002;22(6):449–458. doi: 10.1053/snep.2002.35973.
    1. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16(2):489–495. doi: 10.1681/ASN.2004030203.
    1. Hallan SI, Orth SR. The conundrum of chronic kidney disease classification and end-stage renal risk prediction in the elderly--what is the right approach? Nephron Clin Pract. 2010;116(4):c307–c316. doi: 10.1159/000319166.
    1. Abutaleb N. Why we should sub-divide CKD stage 3 into early (3a) and late (3b) components. Nephrol Dial Transplant. 2007;22(9):2728–2729. doi: 10.1093/ndt/gfm349.
    1. Ito H, Oshikiri K, Mifune M, Abe M, Antoku S, Takeuchi Y, Togane M, Yukawa C. The usefulness of the revised classification for chronic kidney disease by the KDIGO for determining the frequency of diabetic micro- and macroangiopathies in Japanese patients with type 2 diabetes mellitus. J Diabetes Complicat. 2012;26(4):286–290. doi: 10.1016/j.jdiacomp.2012.04.011.
    1. Zhang JJ, Yu GZ, Zheng ZH, Liu YF, Du YY, Quan SX, Liu YJ, Lv JC, Zhang H. Dividing CKD stage 3 into G3a and G3b could better predict the prognosis of IgA nephropathy. PLoS One. 2017;12(4):e0175828. doi: 10.1371/journal.pone.0175828.
    1. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol. 2009;20(5):1069–1077. doi: 10.1681/ASN.2008070730.
    1. Abdel-Kader K, Unruh ML, Weisbord SD. Symptom burden, depression, and quality of life in chronic and end-stage kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1057–1064. doi: 10.2215/CJN.00430109.
    1. Lowrie EG, Curtin RB, LePain N, Schatell D. Medical outcomes study short form-36: a consistent and powerful predictor of morbidity and mortality in dialysis patients. Am J Kidney Dis. 2003;41(6):1286–1292. doi: 10.1016/S0272-6386(03)00361-5.
    1. Rayner HC, Zepel L, Fuller DS, Morgenstern H, Karaboyas A, Culleton BF, Mapes DL, Lopes AA, Gillespie BW, Hasegawa T, et al. Recovery time, quality of life, and mortality in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS) Am J Kidney Dis. 2014;64(1):86–94. doi: 10.1053/j.ajkd.2014.01.014.
    1. Miskulin DC, Abebe KZ, Chapman AB, Perrone RD, Steinman TI, Torres VE, Bae KT, Braun W, Winklhofer FT, Hogan MC, et al. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. Am J Kidney Dis. 2014;63(2):214–226. doi: 10.1053/j.ajkd.2013.08.017.
    1. DeOreo PB. Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance. Am J Kidney Dis. 1997;30(2):204–212. doi: 10.1016/S0272-6386(97)90053-6.
    1. Chin HJ, Song YR, Lee JJ, Lee SB, Kim KW, Na KY, Kim S, Chae DW. Moderately decreased renal function negatively affects the health-related quality of life among the elderly Korean population: a population-based study. Nephrol Dial Transplant. 2008;23(9):2810–2817. doi: 10.1093/ndt/gfn132.

Source: PubMed

3
Subskrybuj